Phase 1b Study of Iberdomide and CC-99282 with R-CHOP for Lymphoma Treatment
A Phase 1b trial is evaluating the safety and efficacy of Iberdomide (CC-220) and CC-99282 combined with R-CHOP for treating lymphoma.
Phase III
Oncology / Lymphoma
Status
Active
Sponsor
R-CHOP
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should monitor the trial's progress as successful outcomes could influence treatment guidelines and market dynamics.
Why it matters
The ongoing Phase 1b trial of Iberdomide and CC-99282 combined with R-CHOP represents a significant opportunity to introduce new treatment options in the lymphoma space. Successful outcomes could reshape treatment guidelines and enhance competitive positioning against existing therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the determination of the Recommended Phase 2 Dose (RP2D) and results from the dose expansion phase.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.